Strategic Blueprint, LLC Moleculin Biotech, Inc. Transaction History

Strategic Blueprint, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 12, 2021	SELL	$2.7 - $3.59 $243 - $323	-90 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$3.21 - $4.06 $288 - $365	90 New	90 $0

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $48.6M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Strategic Blueprint, LLC, based on Form 13F filings with the SEC.

Stay updated on Strategic Blueprint, LLC with notifications on news.